Ren Fei, Wang Depin, Zhang Xueyuan, Zhao Na, Wang Xiaowen, Zhang Yu, Li Li
High Performance Computer Research Center, Institute of Computing Technology, Chinese Academy of Sciences, Beijing, China.
Zhijian Life Co. Ltd., Beijing, China.
Front Genet. 2022 Jun 20;13:846517. doi: 10.3389/fgene.2022.846517. eCollection 2022.
Hepatocellular carcinoma (HCC) is a prevalent malignancy cancer worldwide with a poor prognosis. Hepatic resection is indicated as a potentially curative option for HCC patients in the early stage. However, due to multiple nodules, it leads to clinical challenges for surgical management. Approximately 41%-75% of HCC cases are multifocal at initial diagnosis, which may arise from multicentric occurrence (MO-HCC) or intrahepatic metastasis (IM-HCC) pattern with significantly different clinical outcomes. Effectively differentiating the two mechanisms is crucial to prioritize the allocation of surgery for multifocal HCC. In this study, we collected a multifocal hepatocellular carcinoma cohort of 17 patients with a total of 34 samples. We performed whole-exome sequencing and staining of pathological HE sections for each lesion. Reconstruction of the clonal evolutionary pattern using genome mutations showed that the intrahepatic metastogenesis pattern had a poorer survival performance than independent origins, with variants in the TP53, ARID1A, and higher CNV variants occurring more significantly in the metastatic pattern. Cross-modality analysis with pathology showed that molecular classification results were consistent with pathology results in 70.6% of patients, and we found that pathology results could further complement the classification for undefined patterns of occurrence. Based on these results, we propose a model to differentiate the pattern of multifocal hepatocellular carcinoma based on the pathological results and genome mutations information, which can provide guidelines for diagnosing and treating multifocal hepatocellular carcinoma.
肝细胞癌(HCC)是全球范围内常见的恶性肿瘤,预后较差。肝切除术被认为是早期HCC患者潜在的治愈性选择。然而,由于存在多个结节,这给手术管理带来了临床挑战。大约41%-75%的HCC病例在初诊时为多灶性,其可能源于多中心发生(MO-HCC)或肝内转移(IM-HCC)模式,临床结局显著不同。有效区分这两种机制对于优先分配多灶性HCC的手术至关重要。在本研究中,我们收集了一个由17例患者组成的多灶性肝细胞癌队列,共34个样本。我们对每个病灶进行了全外显子组测序和病理HE切片染色。利用基因组突变重建克隆进化模式显示,肝内转移模式的生存表现比独立起源模式差,TP53、ARID1A中的变异以及更高的拷贝数变异在转移模式中出现得更显著。与病理学的跨模态分析表明,70.6%的患者分子分类结果与病理结果一致,并且我们发现病理结果可以进一步补充对未明确发生模式的分类。基于这些结果,我们提出了一个基于病理结果和基因组突变信息来区分多灶性肝细胞癌模式的模型,该模型可为多灶性肝细胞癌的诊断和治疗提供指导。